Dr. Oddis has devoted his career to the investigation and treatment of inflammatory myopathy with an emphasis on epidemiology, clinical features, autoantibody associations, pathogenesis, and treatment. He has supervised and managed a clinically- and serologically-defined, longitudinal myositis registry of nearly 2,000 patients, developing a web-based Myositis Data Management System, which enables investigators to link disease activity and damage measures with clinical, laboratory and serologic data over time. Dr. Oddis was the Principal Investigator on the RIM (Rituximab in Myositis) Trial, the first multicenter clinical trial in myositis funded by the National Institutes of Health and the largest clinical trial ever completed in adult and pediatric myositis. He authored the Consensus Guidelines for the Conduct of Clinical Trials in Myositis with several colleagues. Dr. Oddis continues to coordinate myositis clinical trials with his faculty collaborators at the University of Pittsburgh including the investigation of autoimmune interstitial lung disease. Over the years, he has served on a number of multidisciplinary panels that have formulated guidelines in the assessment and management of both myositis and ILD.
- BS, University of Pittsburgh, 1976
- MD, Pennsylvania State University College of Medicine, 1980
- Residency, University Hospital, Pennsylvania State University, 1984
- Fellowship, University of Pittsburgh School of Medicine, 1987
Education & Training
Traineau, H., Aggarwal, R., Monfort, J.B., Senet, P., Oddis, C.V., Chizzolini, C., Barbaud, A., Frances, C., Arnaud, L., Chasset, F. Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. Journal of the American Academy of Dermatology. 2020; 82(2): 317-325.
Kass, D.J., Nouraie, M., Glassberg, M.K., Ramreddy, N., Fernandez, K., Harlow, L., Zhang, Y,, Chen, J., Kerr, G.S., Reimold, A.M., England, B.R., Mikuls, T.R., Gibson, K.F., Dellaripa, P.F., Rosas, I.O., Oddis, C.V., Ascherman, D.P. Comparative profiling of serum protein biomarkers in rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis. Arthritis Rheumatology. 2020; 72(3): 409-419.
Saygin, D., Oddis, C.V., Marder, G., Moghadam-Kia, S., Nandkumar, P., Neiman, N., Dzanko, S., Koontz, D., Aggarwal, R. Follow-up results of myositis patients treated with H.P. Acthar gel. Rheumatology (Oxford). Epub ahead of publication. 2020
Eng, S.W.M., Olazagasti, J.M., Goldenberg, A., Crowson, C.S., Oddis, C.V., Niewold, T.B., Yeung, R.S.M., Reed, A.M. A clinically and biologically based subclassification of the idiopathic inflammatory myopathies using machine learning. ACR Open Rheumatology. Epub ahead of publication. 2020
Aggarwal, R., Moghadam-Kia, S., Lacomis, D., Malik, A., Qi, Z., Koontz, D., Burlingame, R.W., Oddis, C.V. Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level. Scandinavian Journal of Rheumatology. 2019; 1-7.
Oddis, C.V. Myopathy for the general internist: Statins and much more. Cleveland Clinic Journal of Medicine. 2019; 86 (10): 656-664.
Moghadam-Kia, S., Charlton, D., Aggarwal, R., Oddis, C.V. Potential role of Janus kinase inhibition with tofacitinib. Rheumatology (Oxford). 2019; 58 (6): 1011-1015.
Charlton, D., Moghadam-Kia, S., Smith, K., Aggarwal, R., English, J.C., Oddis, C.V. Refractory cutaneous dermatomyositis with severe scalp pruritus responsive to apremilast. Journal of Clinical Rheumatology. 2019
Schneider, F, Yousem, S.A., Oddis, C.V., Aggarwal, R. Pulmonary Pathologic Manifestations of Anti-Alanyl-tRNA Synthetase (Anti-PL-12)-Related Inflammatory Myopathy. Arch Pathol Lab Med. 2018; 142(2): 191-197.
Oddis, C.V., Aggarwal, R. Treatment in myositis. Nat Rev Rheumatol. 2018; 14(5): 279-289.
